Artelo Biosciences, Inc. (ARTL) stock
ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.50−0.18 (-10.71%)
Close on Nov 18, 2026Market cap $1.01MP/E –Yield –
Artelo Biosciences total assets
Total assets on the balance sheet at the end of each period.
Artelo Biosciences's total assets was $6.46M at Jun 30, 2026. For fiscal 2025 it was $2.80M, down 40.4% from the year before. Over ten years it grew 69.0% a year on average. The highest annual figure on record is $13.04M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | -40.4% |
| FY2024 | Dec 31, 2024 | $4.70M | -64.0% |
| FY2023 | Dec 31, 2023 | $13.04M | +3.2% |
| FY2021 | Aug 31, 2021 | $12.64M | +188.7% |
| FY2020 | Aug 31, 2020 | $4.38M | -32.5% |
| FY2019 | Aug 31, 2019 | $6.48M | +1532.9% |
| FY2018 | Aug 31, 2018 | $397.00K | -30.9% |
| FY2017 | Aug 31, 2017 | $574.28K | +15896.5% |
| FY2016 | Aug 31, 2016 | $3.59K | -78.9% |
| FY2015 | Aug 31, 2015 | $17.03K | +15.6% |
| FY2014 | Aug 31, 2014 | $14.73K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $6.46M | +48.2% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $12.52M | +256.1% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $2.80M | -40.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $4.27M | -40.2% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $4.36M | -47.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $3.52M | -66.1% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $4.70M | -64.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $7.14M | -54.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $8.33M | -50.7% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $10.35M | -44.0% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $13.04M | +3.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $15.50M | +25.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $16.88M | +25.5% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $18.48M | +93.7% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $12.64M | +188.7% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $12.34M | +253.2% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $13.44M | +223.8% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $9.54M | +71.9% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $4.38M | -32.5% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $3.49M | +202.9% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $4.15M | +757.4% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $5.55M | +3255.0% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $6.48M | +1532.9% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $1.15M | +187.6% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $484.28K | -10.5% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $165.36K | -61.6% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $397.00K | -30.9% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $400.98K | +76.0% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $541.10K | +3920.9% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $430.29K | +11885.7% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $574.28K | +15896.5% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $227.84K | +6246.5% |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $13.46K | +274.8% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $3.59K | -9.6% |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $3.59K | -78.9% |
| Q3 FY2016CQ2 2016 | May 31, 2016 | $3.59K | -71.5% |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $3.59K | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $3.97K | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | $17.03K | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | $12.58K | – |
See a number that looks wrong?